UroGen Pharma Ltd

For the period ended Dec 31, 2024. Filed Mar 10, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 10, 2025

URGN$26.31+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Deficit

(in thousands, except share amounts)

Ordinary Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total
Number of Shares · Amount · Amounts
Balance as of December 31, 2022	23,129,953	$63	$487,787	$(577,104)	$(107)	$(89,361)
Exercise of options into ordinary shares	460,053	1	872			873
Share-based compensation			9,343			9,343
Issuance of pre-funded warrants, net of issuance costs			48,700			48,700
Conversion of pre-funded warrants into ordinary shares	1,599,733	5	(5)			—
Issuance of ordinary shares, net of issuance costs	7,300,380	20	67,338			67,358
Other comprehensive income					119	119
Net loss				(102,244)		(102,244)
Balance as of December 31, 2023	32,490,119	$89	$614,035	$(679,348)	$12	$(65,212)
Exercise of options into ordinary shares	419,731	1	320			321
Share-based compensation			13,108			13,108
Issuance of pre-funded warrants, net of issuance costs			18,641			18,641
Issuance of ordinary shares, net of issuance costs	9,321,896	25	151,144			151,169
Other comprehensive income					44	44
Net loss				(126,874)		(126,874)
Balance as of December 31, 2024	42,231,746	$115	$797,248	$(806,222)	$56	$(8,803)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.